SRR601169
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.353
- IL6_JAK_STAT3_SIGNALING+0.351
- INTERFERON_ALPHA_RESPONSE+0.348
- INTERFERON_GAMMA_RESPONSE+0.345
- INFLAMMATORY_RESPONSE+0.333
- COMPLEMENT+0.239
- IL2_STAT5_SIGNALING+0.197
- PANCREAS_BETA_CELLS+0.183
- KRAS_SIGNALING_UP+0.181
- KRAS_SIGNALING_DN+0.177
Top 10 suppressed
- MYC_TARGETS_V2-0.515
- MYC_TARGETS_V1-0.437
- DNA_REPAIR-0.429
- G2M_CHECKPOINT-0.403
- OXIDATIVE_PHOSPHORYLATION-0.393
- E2F_TARGETS-0.374
- MITOTIC_SPINDLE-0.335
- UNFOLDED_PROTEIN_RESPONSE-0.290
- GLYCOLYSIS-0.230
- PI3K_AKT_MTOR_SIGNALING-0.227
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208964 | — | — | 0.907 |
| 2 | SRR820379 | GTEX | — | 0.905 |
| 3 | R232 | — | — | 0.904 |
| 4 | SRR598671 | GTEX | — | 0.895 |
| 5 | SRR607935 | GTEX | — | 0.894 |
| 6 | MNG1283 | — | — | 0.893 |
| 7 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.891 |
| 8 | SRR1329551 | GTEX | — | 0.888 |
| 9 | SRR607478 | GTEX | — | 0.883 |
| 10 | SRR8943034 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.353 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.351 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.348 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.345 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.333 | Idelalisib | — uncovered |
| COMPLEMENT | 0.239 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.197 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.183 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.181 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.177 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.167 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.157 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.136 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.105 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.102 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| PEROXISOME | 0.097 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.079 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.052 | Inavolisib | — uncovered |